Mercury Lab Peer Comparison

BSE: 538964

₹750.00

₹-48.00 (-6.02%)

As on 06-Nov-2026IST

Market cap

₹90 Cr

Revenue (TTM)

₹74 Cr

P/E Ratio

28.2

P/B Ratio

1.5

Div. Yield

0.5 %

Edit

	Mercury Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	CORONA Remedies
Market cap (₹ Cr)	90	18,433	17,619	17,093	14,916
Revenue (₹ Cr)	74	1,842	2,654	3,330	1,559
Net Profit (₹ Cr)	3.19	308.62	859.38	720.77	206.58
Net Margin (%)	4.25	16.63	30.42	21.60	13.15
RoE (%)	5.94	11.81	18.58	18.93	28.52
Price to Earnings	28.20	55.45	20.50	24.16	72.05
Price-To-Book	1.53	6.68	4.02	4.12	18.53

Income Statement (₹ Cr)

	Mercury Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	CORONA Remedies
Operating Revenue	73.76	1,841.62	2,654.29	3,329.63	1,559.11
Total Income	75.18	1,855.87	2,825.39	3,337.47	1,571.09
Total Expenditure	66.58	1,328.95	1,681.39	2,168.88	1,224.85
EBITDA	7.19	512.67	972.90	1,160.75	334.26
Depreciation	3.18	130.47	57.71	285.40	48.04
EBIT	4.01	382.20	915.19	875.35	286.22
Interest	0.55	49.12	8.91	187.51	8.48
Other Income	1.41	14.25	171.10	7.84	11.98
Exceptional Items	-0.40	11.73	82.90	-53.14	-19.10
Profit before Tax	4.47	359.06	1,160.28	642.54	270.62
Provision for Tax	1.28	50.44	300.90	-78.23	64.04
Profit after Tax	3.19	308.62	859.38	720.77	206.58

	Mercury Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	CORONA Remedies
Shareholder's Funds	58.63	2,757.68	4,385.41	4,144.34	804.07
Minority Interest	0.00	0.00	0.00	-10.85	0.00
Non-Current Liabilities	9.27	363.37	222.21	758.48	108.63
Current Liabilities	13.06	1,016.50	685.36	2,681.14	333.00
Total Liabilities	79.08	3,705.61	4,921.88	7,246.72	--

	Mercury Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	CORONA Remedies
Non-Current Assets	32.30	2,763.86	905.21	5,578.78	719.39
Current Assets	45.28	1,277.15	4,024.56	1,800.86	473.68
Total Assets	79.08	3,705.61	4,921.88	7,246.72	--
Total Debt*	7.41	657.97	2.50	2,309.68	--
Net Current Assets	32.22	260.65	3,339.20	-880.28	140.68
Contingent Liabilities	2.82	160.01	370.49	51.57	--

	Mercury Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	CORONA Remedies
Cash From Operating Activities	4.24	342.18	967.57	537.99	--
Cash Flow from Investing Activities	-3.17	-325.92	-561.67	-369.46	--
Cash from Financing Activities	2.91	13.62	-798.31	-313.53	--
Net Cash Inflow / Outflow	3.99	29.88	-392.41	-145.00	--

	Mercury Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	CORONA Remedies
ROCE (%)	11.66	11.43	23.39	14.47	--
ROE (%)	5.94	11.81	18.58	18.93	28.50
ROA (%)	4.12	8.09	17.36	9.78	18.60
EBIT Margin (%)	5.44	20.75	34.48	26.29	18.36
Net Margin (%)	4.25	16.63	30.42	21.60	13.15
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Mercury Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	CORONA Remedies
Revenue Growth (%)	-4.67	37.26	11.75	11.06	20.02
EBIT Growth (%)	-25.88	56.89	21.45	13.71	22.30
Net Profit Growth (%)	-35.03	127.86	2.39	60.98	18.28
EPS Growth (%)	-29.41	5.65	13.17	80.38	26.45
Book Value Growth (%)	8.41	9.67	-0.34	36.71	--

	Mercury Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	CORONA Remedies
Price / Earnings	25.95	58.38	22.08	22.37	67.54
Price / Book Value	1.53	6.68	4.02	4.12	18.55
Dividend Yield (%)	0.47	0.06	1.95	0.00	0.41
EV/EBITDA	12.69	37.15	14.92	16.66	44.92
Market Cap (₹ Cr)	84.00	6,819.66	21,592.90	17,980.08	--

	Mercury Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	CORONA Remedies
Debt to Equity	0.11	0.08	0.00	0.10	0.00
Short term debt to equity ratio	--	0.16	0.00	0.12	--
Current Ratio	3.47	1.26	5.87	0.67	1.42
Quick Ratio	2.85	0.82	5.23	0.49	0.91
Interest Coverage	9.08	8.31	131.22	4.43	32.91

	Mercury Lab	Shilpa Medicare	Pfizer	Eris Lifesciences	CORONA Remedies
Debtors to sales (%)	35.58	29.09	9.10	18.98	10.94
Asset Turnover	0.95	0.48	0.54	0.45	1.40
Receivable days	123.98	113.81	26.06	63.88	--
Inventory Days	34.44	84.76	65.95	43.27	--
Payable days	147.97	101.94	81.01	151.85	--
Cash Conversion Cycle	10.46	96.62	11.00	-44.70	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.